Tevogen Inc.
- TVGN ยท Nasdaq
- Biological Products, (No Diagnostic Substances)
- Warren, NJ
- CIK 0001860871
Updated from SEC filings through
Top things to know
Next earningsFebruary 12, 2027Estimated from past filings
Latest 8-KDeparture or appointment of directors or officers; compensationFiled November 4, 2026Leadership changeItem 5.02 filedNovember 4, 2026, last 90 days Executives
-
Ryan H. Saadi Chief Executive Officer Form 4, September 16, 2026 -
Kirti Desai Chief Financial Officer 8-K, September 16, 2026 - Neal Flomenberg Chief Scientific Officer and Global R&D Lead DEF 14A, August 3, 2026
Tevogen Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Warren, NJ. It trades as TVGN on Nasdaq.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | Not on file | Not on file | Not on file | Not on file |
| Operating income | -$26.1M 10-K, 2026-03-31 | -$53.6M 10-K, 2026-03-31 | -$8.8M 10-K, 2025-04-02 | Not on file |
| SG&A | $15.0M 10-K, 2026-03-31 | $22.5M 10-K, 2026-03-31 | $4.4M 10-K, 2025-04-02 | $953K 10-K, 2024-04-29 |
| Net income | -$26.3M 10-K, 2026-03-31 | -$13.7M 10-K, 2026-03-31 | -$60.5M 10-K, 2025-04-02 | $4.4M 10-K, 2024-04-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| | Chief Executive Officer | Form 4, September 16, 2026 |
| | Chief Financial Officer | 8-K, September 16, 2026 |
| Neal Flomenberg | Named in proxy bio: Chief Scientific Officer and Global R&D Lead | DEF 14A, August 3, 2026 |
| | Board member (per proxy) bio: Director | DEF 14A, August 3, 2026 |
| | Board member (per proxy) bio: Director | DEF 14A, August 3, 2026 |
| Susan Podlogar | Board member (per proxy) bio: Director | DEF 14A, August 3, 2026 |
What Tevogen Inc. does
Tevogen is a healthcare company focused on addressing unmet needs across biotechnology, technology, and healthcare services.
Company website description, 10-K for the year ending November 7, 2026
Shares and governance
| Shares outstanding | 68.7 million (as of November 16, 2026) | 10-Q, November 16, 2026 |
|---|---|---|
| Public float | $63.7M (as of June 30, 2025) | 10-K/A, April 30, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 16, 2026 |
| Latest proxy statement | Meeting August 3, 2026 (filed August 3, 2026) | DEF 14A, August 3, 2026 |
| Auditor | Kpmg LLP (Philadelphia, Pennsylvania) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| March 13, 2026 | Neal Flomenberg See Remarks | Sale | 972 | $7K | Form 4, March 17, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-11-03
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 3.02 Unregistered sales of equity securities
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-09-30
- Item 8.01 Other events
- 8-K filed 2026-09-16
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-09-10
- Item 8.01 Other events
- 8-K filed 2026-08-26
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-07-30
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- 8-K filed 2026-04-22
- Item 3.01 Notice of delisting or failure to meet listing standards
- 8-K filed 2026-03-25
- Item 8.01 Other events
- 8-K filed 2026-03-04
- Item 3.03 Material modification to rights of security holders
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Tevogen Inc.
- What does Tevogen Inc. do?
- In its own words, from Item 1 of its 10-K: "Tevogen is a healthcare company focused on addressing unmet needs across biotechnology, technology, and healthcare services."
- Who is the CFO of Tevogen Inc.?
- Kirti Desai, Chief Financial Officer, as named in a 8-K filed September 16, 2026.
- Where is Tevogen Inc. headquartered?
- Warren, NJ.
- What is Tevogen Inc.'s stock ticker?
- TVGN, TVGNW on Nasdaq.
- What industry is Tevogen Inc. in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Tevogen Inc.'s website?
- tevogen.com.
- When does Tevogen Inc. report earnings next?
- February 12, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Tevogen Inc. a public company?
- Yes. Tevogen Inc. files with the SEC under CIK 0001860871 and trades as TVGN.
- Who audits Tevogen Inc.?
- Kpmg LLP, Philadelphia, Pennsylvania, as named in its latest annual report (10-K).
- How many shares of Tevogen Inc. are outstanding?
- 68.7 million shares as of November 16, 2026, from its 10-Q filed November 16, 2026.
- What is Tevogen Inc.'s public float?
- $63.7M as of June 30, 2025, as reported on the cover of its 10-K/A filed April 30, 2026.
- How many business segments does Tevogen Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 16, 2026.
- When is Tevogen Inc.'s annual shareholder meeting?
- August 3, 2026, per its proxy statement (DEF 14A) filed August 3, 2026.
- Have Tevogen Inc. insiders traded stock recently?
- Since March 13, 2026, officers and directors reported 1 open-market sale worth about $7K and 0 purchases on Forms 4 and 5. The most recent: Neal Flomenberg (See Remarks) sold 972 shares on March 13, 2026.